To date the company has:
Raised $515,000 of seed capital
Built a preliminary prototype that aims to validate the technology against a human tissue proxy
Had a patent issued for the underlying technology and filed for additional claims (US20130310688A1)
Developed a clinical prototype development plan with a major clinical partner
Established a plan to conduct a clinical study with a major hospital partner